Protecting against future shock - Inhalational anthrax

New England Journal of Medicine

Volumn 361, Issue 2, 2009, Pages 191-193

  Nabel, Gary J ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRAX VACCINE; ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; MONOCLONAL ANTIBODY; RAXIBACUMAB; UNCLASSIFIED DRUG;

ANTHRAX; CLINICAL TRIAL; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; EBOLA VIRUS; EDITORIAL; EPIDEMIC; HERPES VIRUS; HUMAN; INFLUENZA; MARBURG VIRUS; MEDICAL RESEARCH; NONHUMAN; PRIORITY JOURNAL; SMALLPOX; SWINE INFLUENZA VIRUS;

EID: 67650494292     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMe0903259     Document Type: Editorial

References (2)

1. Migone T-S, Subramanian GM, Zhong J, et al. Raxibacumab for the treatment of inhalational anthrax. N Engl J Med 2009; 361:135-44.
2. Sullivan NJ, Martin JE, Graham BS, Nabel GJ. Correlates of protective immunity for Ebola vaccines: implications for regulatory approval by the animal rule. Nat Rev Microbiol 2009;7:393-400.